RxDoctor Payments Data

Roberteen McCray, DO

Family Medicine · Casselberry, FLNPI 1619489622

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 68 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$251
  • AstraZeneca$226
  • Boehringer Ingelheim$190
  • AbbVie$122
  • Otsuka America Pharmaceutical, Inc.$122
  • Neurocrine Biosciences, Inc.$120
  • plus $970 from 17 others

What the payments were for

  • Food & beverage$2,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$280,570
Medicare patients
485
Services billed
3,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$75,313
TrulicityDulaglutide42$18,971
XareltoRivaroxaban46$15,724
ArexvyRsvpref3 Antigen/As01e/Pf49$15,415
ErtapenemErtapenem Sodium38$14,884
ProcritEpoetin Alfa25$13,421
TradjentaLinagliptin20$8,366
SantylCollagenase Clostridium Hist.25$8,131
LinzessLinaclotide12$6,536
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog75$5,769
Atorvastatin Calcium271$4,417
Pantoprazole Sodium129$4,339
SymbicortBudesonide/Formoterol Fumarate14$4,337
Gabapentin178$3,955
Memantine Hcl49$3,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$55$77,918232 claims
Johnson & JohnsonXarelto, Procrit$68$29,14571 claims
GSKArexvy$51$15,41549 claims
Boehringer IngelheimTradjenta$190$8,36620 claims
AbbVieLinzess$122$6,53612 claims
AstraZenecaSymbicort$226$4,33714 claims
MerckJanuvia$12$3,05911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Casselberry

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →